Exciting Leadership Transition at Advancium Health Network
Advancium Health Network has recently appointed Michele Cleary, PhD, as Chief Executive Officer, marking a new era in pediatric healthcare. Dr. Cleary, who previously served as the President and Chief Scientific Officer, brings a wealth of experience to this vital position. With over two decades spent in scientific innovation, drug development, and patient advocacy, she is well-equipped to lead the organization forward.
Transformative Vision for Healthcare
Ron Mitchell, a member of the Board of Directors and Managing Partner at Low Post Ventures, expressed confidence in Dr. Cleary's capabilities. He stated, "Michele's elevation to CEO reflects her unwavering dedication and proven ability to deliver results. She has already transformed our approach to pediatric drug development—building partnerships, identifying a strategic pipeline of high-impact programs, and creating models that challenge conventional timelines. Her leadership positions us to achieve breakthroughs that families urgently need." Dr. Cleary's previous tenure was characterized by notable achievements in fostering collaborations and advancing pediatric drug initiatives.
Expertise Shaping Future Endeavors
Dr. Cleary's background includes extensive experience in translational research, clinical development strategies, and interactions with regulatory bodies such as the FDA. Before her time at Advancium, she held key roles at major pharmaceutical companies like Bristol Myers Squibb and Merck Research Laboratories. She was instrumental in leading academic partnerships and was the founding CEO of the Mark Foundation for Cancer Research. Furthermore, during her time on Advancium's Board of Directors from 2022 to 2024, she provided strategic guidance that played a significant role in the organization's growth.
Commitment to Pediatric Healthcare
Her commitment to improving outcomes for children affected by rare diseases is echoed by industry professionals. Jim Flynn, Managing Partner at Deerfield Management, remarked, "Michele has demonstrated a deep commitment to improving outcomes for children with rare diseases. Her experience and leadership will help Advancium and CobiCure continue to build effective partnerships and deliver meaningful progress for patients and families who need it most." This passion aligns closely with Advancium's mission to provide innovative solutions for underserved populations.
Charting a New Course
In her new role, Dr. Cleary has pledged to accelerate progress in developing transformative solutions for pediatric healthcare. She stated, "I am honored to lead Advancium and CobiCure into this next chapter. Together with our exceptional team and partners, we are redefining what's possible for children with rare diseases. These families cannot wait, and neither will we." Under her leadership, the organization plans to expand its portfolio of medical devices and therapies, while developing deeper collaborations with leading research institutions.
Innovative Approaches to Healthcare
To foster innovation, Advancium and CobiCure aim to implement creative funding models that address the unique healthcare challenges faced by underserved pediatric populations. By leveraging the strengths of its nonprofit status and for-profit infrastructure, Advancium is poised to make a meaningful impact on the lives of children requiring medical interventions.
About Advancium Health Network
Advancium Health Network is committed to overcoming barriers in healthcare through a visionary model that integrates for-profit infrastructure with nonprofit ideals. The organization connects diverse industry partners and experts, leveraging resources to develop pediatric medical devices and therapies. The mission remains clear: confronting the toughest challenges in healthcare for patients and driving positive change.
About CobiCure
CobiCure, the nonprofit subsidiary of Advancium Health Network, seeks to fill critical gaps in pediatric healthcare. By accelerating the development of innovative medical devices and treatments for children facing serious health challenges, CobiCure aims to shift the focus from traditional profit-driven models to life-saving solutions.
Frequently Asked Questions
Who is the new CEO of Advancium Health Network?
Michele Cleary, PhD, has been appointed as the new CEO, bringing extensive experience in scientific innovation.
What prior roles did Michele Cleary hold?
Before becoming CEO, she was the President and Chief Scientific Officer at Advancium and held senior roles at major pharmaceutical companies.
What is the focus of Advancium Health Network?
Advancium is dedicated to pediatric healthcare and aims to create innovative medical solutions for underserved populations.
What initiatives will Michele Cleary pursue as CEO?
She plans to expand healthcare portfolios, deepen collaborations, and enhance funding models for pediatric solutions.
What is the mission of CobiCure?
CobiCure is committed to accelerating pediatric healthcare innovations, prioritizing life-saving solutions over traditional approaches.
